Pivotal bioVenture Partners logo

Pivotal bioVenture Partners

North America, California, United States, San Francisco

Description

Pivotal bioVenture Partners is a San Francisco-based venture capital firm investing in early stage biotechnology companies

Investor Profile

Pivotal bioVenture Partners has made 36 investments, with 3 in the past 12 months and 36% as lead.

Stage Focus

  • Series B (47%)
  • Series C (19%)
  • Series A (11%)
  • Series D (8%)
  • Seed (6%)
  • Undisclosed (3%)
  • Convertible Note (3%)
  • Post Ipo Equity (3%)

Country Focus

  • United States (75%)
  • Iceland (8%)
  • China (6%)
  • Canada (3%)
  • Switzerland (3%)
  • United Kingdom (3%)
  • Ireland (3%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Medical
  • Therapeutics
  • Life Science
  • Health Diagnostics
  • Oncology
  • Artificial Intelligence (Ai)
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Pivotal bioVenture Partners frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 5
Sofinnova Investments
North America, California, United States, Menlo Park
Co-Investments: 7
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 7
CA
North America, Massachusetts, United States, Boston
Co-Investments: 5
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 9
Frazier Healthcare Partners
North America, Washington, United States, Seattle
Co-Investments: 5
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 8
Longitude Capital
North America, California, United States, Menlo Park
Co-Investments: 6
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 7
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 6

What are some of recent deals done by Pivotal bioVenture Partners?

Windward Bio

Basel, Basel-Stadt, Switzerland

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

BiotechnologyLife ScienceMedical
Series AJan 10, 2025
Amount Raised: $200,000,000
Evommune

Palo Alto, California, United States

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

BiotechnologyHealth CareLife Science
Series COct 31, 2024
Amount Raised: $115,000,000
Zenas BioPharma

Waltham, Massachusetts, United States

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

BiopharmaHealth CarePharmaceutical
Series CMay 7, 2024
Amount Raised: $200,000,000
BioAge Labs

Richmond, California, United States

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

BiopharmaBiotechnologyLife ScienceTherapeutics
Series DFeb 13, 2024
Amount Raised: $170,000,000
Avalyn Pharma

Seattle, Washington, United States

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series CSep 27, 2023
Amount Raised: $175,000,000
Evommune

Palo Alto, California, United States

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

BiotechnologyHealth CareLife Science
Series BApr 26, 2023
Amount Raised: $50,000,000
Heranova Lifesciences

Huangpu, Shanghai, China

Hekaiwei is a provider of innovative solutions for women's health.

Health CareMedical
SeedMar 8, 2023
Amount Raised: $10,000,000
Oculis

Reykjavík, Gullbringusysla, Iceland

Oculis is a clinical-stage biopharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 3, 2023
Amount Raised: $91,000,000
Zenas BioPharma

Waltham, Massachusetts, United States

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

BiopharmaHealth CarePharmaceutical
Series BNov 7, 2022
Amount Raised: $118,000,000
Plexium

San Diego, California, United States

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Series BFeb 23, 2022
Amount Raised: $102,000,000